Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Against a backdrop of insatiable demand for compute, Web3 principles and technologies offer enterprises transparent, flexible ...
Jan. 12, 2026 Weight-loss drugs like Ozempic and Wegovy are changing how Americans spend money on food. A large Cornell study found households cut grocery spending by over 5% within six months, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback